Anchor Investment Management’s CRISPR Therapeutics CRSP Stock Holding History

Anchor Investment Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-40	Closed	-$1.63K	–	988
2022 Q4	$1.63K	Sell	40 -100	-71%	-$5.3K	﹤0.01%	882
2022 Q3	$9.15K	Hold	140	–	–	﹤0.01%	730
2022 Q2	$8.51K	Hold	140	–	–	﹤0.01%	756
2022 Q1	$8.79K	Hold	140	–	–	﹤0.01%	772
2021 Q4	$10.6K	Buy	140 +100	+250%	+$8.74K	﹤0.01%	778
2021 Q3	$4.48K	Hold	40	–	–	﹤0.01%	795
2021 Q2	$6.48K	Hold	40	–	–	﹤0.01%	775
2021 Q1	$4.87K	Hold	40	–	–	﹤0.01%	785
2020 Q4	$6.12K	Hold	40	–	–	﹤0.01%	725
2020 Q3	$3.35K	Hold	40	–	–	﹤0.01%	766
2020 Q2	$2.94K	Buy	+40	New	+$2.34K	﹤0.01%	753

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Anchor Investment Management's CRSP Position: Q1 2023 in Review

Anchor Investment Management sold out of CRISPR Therapeutics (CRSP) in Q1 2023, closing a stake of 40 shares — an estimated $1.63K sold.

Anchor Investment Management first reported a position in CRSP in Q2 2020 and held it in 11 quarters. The position peaked at $10.6K in Q4 2021. 381 funds tracked by Wall St. Rank hold CRSP as of Q1 2023.

Anchor Investment Management reported no remaining CRISPR Therapeutics position as of Q1 2023 after selling out during the quarter.
Anchor Investment Management sold 40 CRISPR Therapeutics shares in Q1 2023, an estimated $1.63K.
Anchor Investment Management first reported a position in CRISPR Therapeutics in Q2 2020 and held it in 11 quarters.
Anchor Investment Management's CRISPR Therapeutics position peaked at $10.6K in Q4 2021.
381 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2023.

Based on Anchor Investment Management's 13F filing for Q1 2023, filed 2 Jan 2024.